Abstract
There are now several agents tailored for improving dyslipidaemic lipid profiles that have passed the preclinical testing and are presently in clinical trials. The two major fields for these new lipid drugs are:
-
1.
To lower the levels of apoB-containing (atherogenic) lipoproteins, i.e. LDL, VLDL and Lp(a).
-
2.
To increase the levels of apoA-containing (protective) lipoproteins, i.e. HDL.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Healthcare, a part of Springer Science+Business Media
About this chapter
Cite this chapter
Carlson, L.A. (2011). Lipid-modifying agents under development. In: Comprehensive lipid testing and management. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-33-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-908517-33-3_14
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-907673-03-0
Online ISBN: 978-1-908517-33-3
eBook Packages: MedicineMedicine (R0)